Health, Medical, Research, Science

Vitamin D: Who should take it?

HEALTH

Intro: Vitamin D’s main role is in helping your body to absorb calcium from food. If you don’t get enough, the body draws calcium out of your bones

As the winter nights draw closer, many of us will be reaching for the vitamin D tablets. One of the UK’s most popular supplements, the “sunshine vitamin” is known to be essential for healthy bones, teeth, and muscles – and the NHS advises all adults to take a daily 10mcg supplement from October/November to April, when the sun’s rays are too weak for our skin to make it.

Many older people also take it year-round (as the skin’s production of it declines with age and they spend less time outdoors). More recently, research has suggested it also plays an important role in immunity and may even help to prevent dementia and cancer.

But a new study appears to raise questions about who really needs it.

Published in the British Medical Journal (BMJ), the research showed that vitamin D supplements made no meaningful difference to whether older people suffered bone fractures.

The accepted wisdom is that supplements are vital during winter months because of the low position of the sun in the sky. Susan Lanham-New, a professor of nutrition at the University of Surrey and a leading expert on vitamin D, explains: “When UV rays hit our skin, it triggers sterol 7-DHC [a precursor of vitamin D] that sits just under the skin, to commence production of an active form of the vitamin.”

In the UK, ten to 15 minutes of midday sun on bare skin in spring and summer is generally considered sufficient to manufacture our body’s recommended daily need for 10mcg. But the weaker rays in the winter months do not contain the UVB rays that our bodies need to make it, says Professor Lanham-New.

Vitamin D’s main role is in helping your body to absorb calcium from food. If you don’t get enough, the body draws calcium out of your bones. Over time, this makes them more fragile, raising the risk of fractures and osteoporosis (which affects more than three million Britons).

Although certain foods, including oily fish, eggs and fortified breakfast cereals contain modest amounts, you’re only likely to get about a third of your daily requirement from food at best.

About one in six adults in the UK is deficient in vitamin D – and the figure rises to one in three during winter months.

The NHS recommendation to take a supplement is based on the evidence for the nutrient’s crucial role in bone health and follows a 2016 recommendation by an independent committee of experts, the Scientific Advisory Committee on Nutrition (SACN).

Earlier this year, however, the recommendation was challenged as being too low by a group of UK doctors. They argued in the journal Frontiers in Endocrinology that the definition of vitamin D deficiency – a blood level of anything under 25nmol/l – should be increased to 50nmol/l, the threshold used by the World Health Organisation, the US National Academy of Medicine and the European Food Safety Authority.

The doctors cited the fact that, although uncommon, rickets – weak bones due to a lack of vitamin D – has not been wiped out, with about 480 hospital cases in year in England alone. Another argument is that people with obesity, those with darker skin (which absorbs less from the sun) and people in deprived areas who may not have sufficient quantities in their diet, were more likely to be deficient.

Vitamin D intake from food has also fallen, partly because people are eating less meat and fish.

TWO

Vitamin D also plays a critical role in immunity and in preventing cardiovascular disease, cancer, and dementia. People who are severely deficient in it are 33 per cent more likely to be hospitalised with respiratory infections, according to a recent study by the University of Surrey. The researchers analysed data from 36,000 adults and found that those with a severe vitamin D deficiency – classed as a blood concentration below 15nmol/l – were a third more likely to be admitted to hospital with infections such as flu, pneumonia and bronchitis, compared to those with levels over 75nmol/l. They concluded that taking adequate vitamin D could protect against respiratory infections.

The vitamin is also thought to play a role in heart and brain health, by regulating inflammation, blood pressure-related hormones and the function of blood vessels, which could in theory reduce artery damage and high blood pressure. Laboratory research suggests it might also slow cancer cell growth and limit damaging inflammation (by enhancing immune cell function). According to Eamon Laird, a lecturer of nutrition and health at Atlantic Technological University, Sligo, Ireland, as we get older, our immune systems become less efficient and produce inflammatory molecules that circulate more freely in the body, potentially causing damage and disease. It is thought vitamin D might help to regulate this.

A US study also found that older adults who took high doses (125mcg) of the vitamin daily scored higher on memory and cognitive tests than those who didn’t take it. These findings were reported in the journal Sleep Medicine in August.

In addition, it protects cells from “rusting” caused by unstable molecules in the body and environment, and may help immune cells to remove the sticky amyloid plaques which build up in those with dementia.

Nonetheless, these results on cognition should be treated with caution, says Paresh Malhotra, a professor of clinical neurology at Imperial College London. “This was an exploratory study: The number of people studied was low and there was no before and after comparison,” he said.

He adds that the study merely used a questionnaire “to determine who took vitamin D supplements” and did not measure the vitamin D levels in participants.

THREE

More concerning is whether the latest research that shows no meaningful improvement in bone health among older people raises questions about the key reason to take vitamin D supplements in the first place.

The BMJ study pooled results from 69 trials, involving 154,000 adults aged over 65, and found that taking vitamin D made no difference to fracture rates over the following 2.5 years.

The authors concluded that the evidence “does not support routine supplementation” to prevent fractures, and they speculated that older people may be better spending their time and money on resistance exercise and balance training, which have a proven track record in this regard.

This echoes earlier large trials, including a study published in the New England Journal of Medicine in 2019, which found that taking 50mcg of vitamin D a day did not prevent fractures in generally healthy middle-aged and older people. It also did not prevent cancer or heart disease.

A study in 2022 involving 21,000 older Australians who took a monthly vitamin D pill (1,500mcg) for up to five years found that it didn’t reduce overall deaths or cancer or cardiovascular deaths.

However, Professor Lanham-New says that these trials largely involved people who already had healthy levels of the vitamin and “there’s little evidence that giving extra vitamin D to those with adequate amounts will give extra protective benefits”.

So who should take it?

Professor Lanham-New says the recommended daily supplement of 10mcg is enough to keep most people’s blood level above 25nmol/l in the winter months.

In addition, those who spend little time outdoors, including many care home residents, and people with darker skin tones whose skin makes less vitamin D from sunlight, should all take a year-round supplement, she says.

Standard
Artificial Intelligence, Research, Science, Society, Technology

Superintelligent AI and its threat to humanity

ARTIFICIAL INTELLIGENCE

Intro: Humanity faces an uncertain fate as experts brace for superintelligent AI. The tech industry claims looming “singularity” will change everything

Every time one of the world’s top artificial intelligence companies unveils a new system, employees at the US research organisation METR put it through its paces. Its ability is tested to complete a series of increasingly complex tasks.

The tasks are measured by how long each one would take a skilled human. They range from trivial arithmetic (two seconds) and completing a game of Wordle (13 minutes) to building complex military satellite software (taking a human expert 14.5 hours).

The test then serves as a gauge as to how capable AI has become – and where it might go.

The first version of ChatGPT, released in 2022, could only perform simple tasks that would take a human a few seconds.

But as AI systems have become more powerful, they are able to complete more complex actions that would take humans hours or days, such as breaking into a medical website and downloading all its data.

METR has found that AI capabilities are doubling in power every 196 days. Plotted on a graph, this progress starts slowly then rapidly accelerates to a near-vertical plane.

Converse with anyone in the AI industry for any length of time and the likelihood of them pulling up a version of the chart approaches 100pc, to the point where it has become a meme in its own right. It is being referred to as the most important chart in the world. The chart goes off the scale.

Last month, the AI lab Anthropic announced it had developed a new system, called Mythos, that it said was too powerful to release to the public because of its ability to find gaping holes in online security systems.

When METR’s researchers released the results of Mythos’s capability and function, they scored the system at 16 hours – meaning the world’s most powerful AI can now automate tasks that would take a human two full eight-hour shifts.

Nonetheless, they said the model was “at the upper end” of their ability to test. In other words, progress has become too fast for them to measure.

Not everybody is convinced by the results because the test only measures if a machine can do something half the time, not if it can do it consistently. The METR chart has, however, captured many people’s imaginations for two reasons.

First, the exponential growth looks strikingly similar to “Moore’s Law”, the maxim that has governed the electronics industry for more than half a century, stating that microchips roughly double in power every two years.

Second, it measures abilities, rather than intelligence. While many AI “benchmarks” resemble university exams and gradings, dealing in abstract reasoning or maths, the METR test studies whether AI can actually work.

It suggests that on current trends, vast amounts of human tasks could be automated in the next couple of years – including, most crucially of all, the art of developing AI models itself.

At that threshold, known in the tech industry as “recursive self-improvement”, all bets are off.

The concept is closely linked to superhuman AI because an AI that can make itself smarter could act like an evolutionary chain reaction, rapidly building to a system vastly more capable than mankind.

AI would have become – as IJ Good, the Bletchley Park codebreaker, predicted in 1965 – “the last invention that man need make”. Almost Orwellian in thought.

For 60 years, the idea seemed out of reach. But much of Silicon Valley believes this is about to change – and the US government is starting to notice.

The vast majority of people’s experience of AI has not changed much in the last couple of years. The release of ChatGPT in 2022 generated an initial flurry of excitement and fear in equal measure but, since then, progress has been less obvious.

The AI experience for many people comes in seeing an obviously fake video on their social media feeds, seeing an AI overview at the top of their search results, or having a bot that “helpfully” offers to summarise their emails.

But at the coalface, people are rapidly bringing forward their timelines for the day that superintelligence arrives.

Standard
Health, Medical, Research, Science

Blood test that can detect Alzheimer’s 15 years before onset

ALZHEIMER’S DISEASE

A SIMPLE blood test can detect Alzheimer’s disease up to 15 years before symptoms begin, a major trial has found. It paves the way for a national screening programme.

The trial found that the test was as accurate as the current gold standard for diagnosing the condition.

For the first time, doctors were able to say if a person had a high, medium, or low chance, of having the disease – ruling out further invasive procedures.

Experts have said it would “revolutionise” diagnosis, making Alzheimer’s as easy to test and detect as for other routine health conditions such as high cholesterol.

Patients could expect results within days of visiting their GP, rather than the years it currently takes to get a diagnosis. This could have huge implications for future treatments, removing the barriers for a diagnosis – such as long waits for spinal taps or brain scans – and speeding up trials.

It could also pave the way for screening over-50s once more effective treatments become available.

Made by diagnostics company ALZpath, it was found to be 97 per cent accurate at detecting traces of the “tau” protein, which was linked to developing Alzheimer’s disease during the eight-year trials. These proteins start to build up on the brain 10 to 15 years before symptoms start showing.

Researchers in Sweden found high levels of the “tau” protein in the blood test corresponded to high levels of Alzheimer markers seen in expensive diagnostic brain scans and painful lumbar punctures.

The more of this leaked “tau” brain protein in the blood, the more likely or advanced the Alzheimer’s disease was in the tests involving 786 people. Growing evidence suggests biomarker changes like these can be detected in the blood years before other signs of the disease appear in the brain.

It means if scientists can find a way to stop these protein levels from rising, they could effectively halt Alzheimer’s in its tracks.

With breakthrough treatments such as donanemab and lecanemab on the horizon, experts say it is vital to have quick and reliable diagnoses. Professor David Curtis of University College London Genetics Institute said this was “one half of the solution”, while we await effective treatments.

He added: “This potentially could have huge implications. Everybody over 50 could be routinely screened every few years, in much the same way as they are now screened for high cholesterol.”

Around 900,000 people in the UK live with dementia – with Alzheimer’s the most common form. The growing ageing population means numbers are expected to rise to 1.6million by 2040, making a cheap screening tool vital to get to grips with the challenge.

Alzheimer’s Research UK analysis found 74,261 people died from dementia in 2022 compared with 69,178 a year earlier, making it the country’s biggest killer. While previous blood tests have shown promise, these findings have caused particular excitement given the high accuracy levels, large study size, and because the test already exists commercially.

It is also the first time a blood test has been found to be at least as good as a painful lumbar puncture or spinal tap for detecting elevated levels of the tau protein, according to the research team at the University of Gothenburg, Sweden.

Lumbar punctures involve taking fluid from the patient’s spinal cord. The inexpensive tests – priced at around £150 – could also be used to monitor a patient’s condition, allowing more tailored trials or treatment in future.

Dr Richard Oakley, of the Alzheimer’s Society, urged that more research would be needed, but said: “This study is a huge welcome step in the right direction as it shows that blood tests can be just as accurate as more invasive and expensive tests.

“It suggests results from these tests could be clear enough to not require follow-up investigations for some people living with Alzheimer’s disease, which could speed up diagnosis.”

The tests would need regulatory approval before widespread use. But they could form part of NHS trials starting imminently and looking to roll out blood tests for Alzheimer’s within the next five years.

The scientists’ findings were first published in JAMA Neurology.

Standard